How to buy Alimera Sciences stock | $10.5

Alimera Sciences, Inc is a drug manufacturers-specialty & generic business based in the US. Alimera Sciences shares (ALIM) are listed on the NASDAQ and all prices are listed in US Dollars. Alimera Sciences employs 130 staff and has a trailing 12-month revenue of around 0.00.

Alimera Sciences stock price (NASDAQ: ALIM)

Use our graph to track the performance of ALIM stocks over time.

Alimera Sciences shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$10.50
52-week range	$3.82 - $12.25
50-day moving average	$9.24
200-day moving average	$9.17
Wall St. target price	$16.38
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.30

Buy Alimera Sciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Alimera Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Alimera Sciences, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Alimera Sciences price performance over time

Historical closes compared with the close of $10.5 from 2021-05-28

1 week (2021-07-20)	N/A
1 month (2021-07-01)	15.13%
3 months (2021-04-30)	2.54%
6 months (2021-01-27)	N/A

1 year (2020-07-27)	N/A
2 years (2019-07-27)	N/A
3 years (2018-07-27)	N/A
5 years (2016-07-27)	N/A

Is Alimera Sciences under- or over-valued?

Valuing Alimera Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alimera Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Alimera Sciences's EBITDA

Alimera Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.8 million.

The EBITDA is a measure of a Alimera Sciences's overall financial performance and is widely used to measure a its profitability.

Alimera Sciences financials

Revenue TTM	$47.5 million
Gross profit TTM	$43.9 million
Return on assets TTM	-4.69%
Return on equity TTM	0%
Profit margin	-16.4%
Book value	$-0.48
Market capitalisation	$60.2 million

TTM: trailing 12 months

Shorting Alimera Sciences shares

There are currently 185,064 Alimera Sciences shares held short by investors – that's known as Alimera Sciences's "short interest". This figure is 1.1% down from 187,193 last month.

There are a few different ways that this level of interest in shorting Alimera Sciences shares can be evaluated.

Alimera Sciences's "short interest ratio" (SIR)

Alimera Sciences's "short interest ratio" (SIR) is the quantity of Alimera Sciences shares currently shorted divided by the average quantity of Alimera Sciences shares traded daily (recently around 15512.489522213). Alimera Sciences's SIR currently stands at 11.93. In other words for every 100,000 Alimera Sciences shares traded daily on the market, roughly 11930 shares are currently held short.

However Alimera Sciences's short interest can also be evaluated against the total number of Alimera Sciences shares, or, against the total number of tradable Alimera Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alimera Sciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Alimera Sciences shares in existence, roughly 30 shares are currently held short) or 0.0421% of the tradable shares (for every 100,000 tradable Alimera Sciences shares, roughly 42 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Alimera Sciences.

Find out more about how you can short Alimera Sciences stock.

Alimera Sciences share dividends

We're not expecting Alimera Sciences to pay a dividend over the next 12 months.

Have Alimera Sciences's shares ever split?

Alimera Sciences's shares were split on a 1:15 basis on 14 November 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alimera Sciences shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Alimera Sciences shares which in turn could have impacted Alimera Sciences's share price.

Alimera Sciences share price volatility

Over the last 12 months, Alimera Sciences's shares have ranged in value from as little as $3.821 up to $12.25. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alimera Sciences's is 1.8275. This would suggest that Alimera Sciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Alimera Sciences overview

Alimera Sciences, Inc. , a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Frequently asked questions

What percentage of Alimera Sciences is owned by insiders or institutions?
Currently 22.2% of Alimera Sciences shares are held by insiders and 36.079% by institutions. How many people work for Alimera Sciences?
Latest data suggests 130 work at Alimera Sciences. When does the fiscal year end for Alimera Sciences?
Alimera Sciences's fiscal year ends in December. Where is Alimera Sciences based?
Alimera Sciences's address is: 6120 Windward Parkway, Alpharetta, GA, United States, 30005 What is Alimera Sciences's ISIN number?
Alimera Sciences's international securities identification number is: US0162592028 What is Alimera Sciences's CUSIP number?
Alimera Sciences's Committee on Uniform Securities Identification Procedures number is: 016259103